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Abstract: Niemann-Pick disease type C (NP-C) is an autosomal recessive disorder characterized 
by progressive neurological deterioration leading to premature death. The disease is caused by 
mutations in one of two genes, NPC1 or NPC2, leading to impaired intracellular lipid transport 
and build-up of lipids in various tissues, particularly the brain. Miglustat (Zavesca®), a reversible 
inhibitor of glycosphingolipid synthesis, has recently been authorized in the European Union, 
Brazil and South Korea for the treatment of progressive neurological symptoms in adult and 
pediatric patients, and represents the first specific treatment for NP-C. Here we review current 
data on the pharmacology, efficacy, safety and tolerability of miglustat in patients with NP-C, 
based on findings from a prospective clinical trial, preclinical and retrospective studies, and 
case reports. Findings demonstrated clinically relevant beneficial effects of miglustat on neu-
rological disease progression in adult, juvenile and pediatric patients with NP-C, particularly 
those diagnosed in late childhood (6–11 years) and in juveniles and adults (12 years and older), 
compared with those diagnosed in early childhood (younger than 6 years). Miglustat therapy 
was well-tolerated in all age groups. With the approval of miglustat, treatment of patients with 
NP-C can now be aimed toward stabilizing neurological disease, which is likely the best attain-
able therapeutic goal for this disorder.
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Introduction
Niemann-Pick disease type C (NP-C) is a rare, panethnic, autosomal recessive disease 
with an incidence estimated at between 1:120,000 and 1:150,000 live births.1–3 NP-C is 
characterized by progressive neurological deterioration leading to premature death. 
The disease is caused by mutations in either one of two genes, NPC1 or NPC2. NPC1 
gene mutations are present in 95% of cases, and NPC2 mutations are present in 
approximately 4%.4–7 The remainder of patients are biochemically-proven cases who 
do not have identified mutations.
Mutations in NPC1 and NPC2 give rise to severe abnormalities in the intracel-
lular transport of lipid, notably cholesterol, glycosphingolipids and sphingosine.8–12 
The NPC1 or NPC2 gene products normally function cooperatively in intracellular lipid 
transport,8,13,14 and so impaired function leads to the accumulation of lipids in the late-
endosomal and lysosomal intracellular compartments, resulting in the build-up of excess 
lipids in various tissues. In the liver and spleen, excess storage of unesterified cholesterol, 
sphingomyelin, bis(monoacylglycero)phosphate, glycosphingolipids and sphingosine 
can lead to visceral symptoms such as organomegaly and liver dysfunction,15–18 while 
increased levels of glucosylceramide, lactosylceramide, and particularly GM2 and GM3 Therapeutics and Clinical Risk Management 2009:5 878
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gangliosides in the brain could contribute to the neurological 
manifestations of the disease.19
NP-C has an extremely heterogeneous clinical presenta-
tion characterized by a wide range of symptoms that are not 
specific to the disease, and which arise and progress over 
varied periods of time.1,7 Presenting manifestations differ 
according to the individual patient and are heavily dependent 
on the patient’s age at the onset of disease. Diagnosis can 
therefore be difficult and is often delayed by several years 
after presentation of the first symptoms. A clinical diagnosis 
of NP-C requires in-depth screening for characteristic neuro-
logical (as well as systemic) features, and must be confirmed 
by laboratory biochemical and/or molecular genetic testing.1,3 
The key laboratory diagnostic test for NP-C is filipin staining 
of cultured skin fibroblasts from the patient, to demonstrate 
free cholesterol accumulation in lysosomes secondary to 
impaired intracellular cholesterol transport.20 Evaluation of 
the rate of intracellular cholesterol esterification is a useful 
complementary test.20 Molecular genetic testing for NPC1 
and NPC2 gene mutations is also vital to confirm diagnoses 
in patients with a variant biochemical phenotype, as well as 
to enable early and reliable prenatal diagnosis.20
Until recently, treatment for NP-C has been limited to 
supportive measures, for relief of specific manifestations of 
the disease. Anti-epileptics to control seizures, antidepres-
sants for treatment of cataplexy and anticholinergics to 
control tremor and dystonia may all be employed to help 
improve the quality of life of NP-C patients.3,21,22 Systemic 
manifestations, such as gastrointestinal symptoms can be 
managed with anti-diarrheal medications, and simple mea-
sures such as softening of food for patients with dysphagia 
can also be beneficial.3
A number of experimental disease-specific therapies, 
based on the molecular pathology of NP-C, have been tested 
in cell culture and animal models. These include neuros-
teroids and cholesterol-binding agents, which have been 
shown to delay the progression of disease in animal models 
of NP-C.23–25 Direct or indirect overexpression of the GTPase, 
Rab 9, has been shown to reverse the NP-C phenotype in tis-
sue culture26,27 and reduce stored lipids and prolong lifespan 
in a mouse model of NP-C.28 Recently, curcumin has been 
suggested to have beneficial effects on intracellular calcium 
homeostasis and lipid metabolism in NPC1-mutant mice.29 
However, data from clinical studies are required to assess the 
possible role of these compounds in NP-C therapy.
Miglustat (Zavesca®; Actelion Pharmaceuticals Ltd, 
Allschwil, Switzerland) is the first and only approved therapy 
for patients with NP-C. Miglustat is a small iminosugar 
molecule that reversibly inhibits glycosphingolipid 
synthesis.30 Miglustat is approved in the European Union 
(EU), USA, Canada, Brazil, Australia, Turkey, Israel, 
Switzerland, South Korea and New Zealand for the treatment 
of patients with mild to moderate type 1 Gaucher disease 
(GD1) for whom enzyme replacement therapy (ERT) is 
unsuitable or not a therapeutic option. Recently, the EU 
Commission extended miglustat’s indication to include the 
treatment of progressive neurological manifestations in adult 
patients and pediatric patients with NP-C. This was followed 
by authorization in Brazil and South Korea. These approvals 
were based on findings from preclinical studies, a prospec-
tive clinical trial and a retrospective cohort study. Here we 
review the current literature on the pharmacology, efficacy, 
safety and tolerability of miglustat in NP-C.
Neurological manifestations  
in NP-C
Both the symptomatology and the rate of disease progression 
of NP-C are heavily influenced by the age of the patient at the 
onset of disease.1,3,31–33 In neonates and infants, NP-C typically 
manifests as organomegaly and severe liver dysfunction, 
while later onset forms are primarily neurological in nature. 
In late infantile-onset patients, NP-C typically presents 
as ataxia, cognitive impairment and clumsiness. Impaired 
vertical saccadic eye movements are invariably present, 
but are often overlooked. Gelastic cataplexy and epileptic 
seizures are also common; progressive dystonia, dysphagia 
and dysarthria manifest as the disease advances.34–36 These 
manifestations also feature in juvenile- or adult-onset 
disease; however learning disabilities (often leading to school 
failure), behavioral problems, psychiatric signs and slowly-
progressive motor problems are also common in these age 
groups.3,31,33,37,38 Cognitive impairment and dementia are most 
commonly seen in adult-onset patients.
In an observational retrospective study of the natural 
history of neurological disease in 57 patients with NP-C,31 
patients were assessed using a modified version of an 
NP-C specific disability scale,32 which rated the severity 
of defects in ambulation, manipulation, language and 
swallowing. Overall, the rate of neurological deterioration 
was similar across all four measures. However, progres-
sion of neurological disease was consistently more rapid 
in patients who were diagnosed during early childhood 
(younger than 6 years), compared with those diagnosed 
in late childhood (6 to 11 years) or with juvenile or adult 
presentation (12 years or older)31 (Figure 1). Similarly, 
studies of patients with NP-C in the UK and Spain have Therapeutics and Clinical Risk Management 2009:5 879
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also indicated a more rapid progression of disease and early 
death in patients with early-onset NP-C, and slower, more 
subtle progression in juvenile- and adult-onset patients.32,33 
A study in patients with NP-C in the US has also recently 
demonstrated linear disease progression, but did not detect 
a link between age of onset and the rate of progression.37 
This was likely due to the small size and varied nature of the 
patient cohort, which had very few juvenile or adult-onset 
patients. In addition, patients were undergoing various 
therapies during the study, which may have confounded 
the study results.
Since NP-C is primarily a neurological disease, at least in 
patients whose symptoms develop in early childhood or later, 
any effective treatment for NP-C needs to be able to cross 
the blood–brain barrier in order to prevent further neuronal 
damage. While the precise sequence of neuropathological 
changes leading to neurological disease progression in NP-C 
is not currently clear, it is considered likely that symptoms 
arise from two populations of brain cells: those that have 
been lost via cell death and those that are dysfunctional, 
but still viable. In either case, permanent neuronal damage 
will already have occurred by the time most patients are 
diagnosed with NP-C. One study has suggested that the 
appearance of clinical symptoms may indicate that overall 
neuronal impairment has reached a threshold level, and that 
pathological functional changes have become irreversible.37 
There is the possibility that certain symptoms of NP-C could 
be associated with dysfunctional (but still living) cells. 
However, given the vast heterogeneity of neuropathologies 
and clinical neurological manifestations in NP-C, it is not 
currently considered possible to discern whether changes 
(improvement or deterioration) in certain symptoms may 
be related to direct therapeutic effects on subpopulations of 
brain cells, or just a product of patient-to-patient variability. 
Overall, experts agree that in most patients with NP-C, sta-
bilization of neurological disease is likely the best attainable 
therapeutic goal.3 Therapeutic benefits with miglustat in 
NP-C are therefore considered in terms of delaying or halting 
the progression of neurological manifestations of NP-C.
Due to the heterogeneous nature of neurological 
manifestations in NP-C, the choice of clinical endpoints 
and monitoring techniques is vast. So far, no clinical tools 
have been validated for monitoring disease progression in 
patients with NP-C; nevertheless, clinical studies are a source 
of valuable information on which assessment measures may 
have the most clinical utility. The functional disability scale 
used by Iturriaga et al32 and modified for the observational 
study of neurological disease progression in NP-C,31 incor-
porates four parameters of disease that are clinically relevant 
across all age groups that typically experience neurological 
manifestations, and is a simple, easy-to-use instrument for the 
assessment of progression of neurological disease. Although 
it has yet to undergo formal validation studies, the scale has 
been shown to be capable of detecting differences in severity 
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Figure 1 Change in composite disability score over time for overall NP-C population (n = 57) and by age at diagnosis group (untreated patients).  Reproduced with 
permission from   Wraith  Je, Guffon N, Rohrbach M, et al. Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study. 
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and progression rates between different age subgroups of 
patients with NP-C.31,32
One limitation of the functional disability scale is that 
it does not capture psychiatric symptoms; for patients with 
psychiatric impairment, various neuropsychiatric evaluations 
are available, including the Mini-Mental State Examination 
(MMSE) as a general measure of cognition,39 and the Frontal 
Assessment Battery (FAB),40 which evaluates cognitive 
domains that are most commonly affected in NP-C, particu-
larly late-stage patients with predominantly frontal dementia. 
Magnetic resonance imaging (MRI) may also be a useful 
measure for detecting these late changes, particularly for 
the detection of cerebellar atrophy in later stages of disease. 
In addition, proton magnetic resonance spectroscopic imag-
ing (H-MRSI), by evaluation of choline/creatine ratios, has 
been proposed as a more sensitive imaging technique to 
monitor disease progression in NP-C.41
As supranuclear gaze palsy is a common neurological 
manifestation of NP-C that occurs across the age groups, 
ophthalmic measures, such as saccadic eye movement 
(SEM), have been employed to measure the effect of 
treatment on neurological manifestations in patients with 
NP-C.42 Specialized assessments of SEM can be conducted 
based on video-recorded eye movements, and subsequent 
computerized measurements of peak velocity, amplitude 
and duration of either or both of horizontal or vertical eye 
movements. However, the clinical validity of SEM data has 
been questioned; there is some debate over whether these 
measures are related to overall disease severity, as they do not 
always correlate with other clinical parameters.43 SEM data 
may therefore not fully detect clinical benefit from treatment 
in patients with NP-C.
Pharmacology and 
pharmacokinetics of miglustat
Mode of action
Miglustat is a small iminosugar molecule that acts as a com-
petitive inhibitor of the enzyme glucosylceramide synthase, 
which catalyzes the first committed step in glycosphin-
golipid (GSL) synthesis, the glycosylation of ceramide.30 
This inhibits the synthesis of all glucosylceramide-derived 
glycosphingolipids. The inhibition of GSL synthesis by 
miglustat has been demonstrated to reduce pathological 
intracellular lipid storage, improve fluid-phase endosomal 
uptake and normalize lipid transport in peripheral blood B 
lymphocytes of NP-C patients.44 This leads to a reduction of 
the potentially neurotoxic accumulation of gangliosides GM2 
and GM3, lactosylceramide and glucosylceramide, and may 
prevent further neuronal damage. This is thought to be the 
primary mode of action of miglustat in NP-C.
Recent studies have suggested that miglustat indirectly 
modulates intracellular calcium homeostasis through its 
effects on glucosylceramide levels.45 There is evidence to 
suggest that impaired calcium homeostasis related to sphin-
gosine storage may be an initiating factor in the pathogenesis 
of NP-C.29 Sphingosine accumulates in the lysosomes of 
NPC1-mutant cells, and this is thought to inhibit lysosomal 
calcium uptake, as demonstrated in a study using human and 
mouse NPC1-mutant cells.29 Depletion of lysosomal calcium 
leads to impaired endocytic function and subsequent lipid 
storage, thus inducing the NP-C disease phenotype. The 
effect of miglustat on intracellular calcium levels might 
therefore influence an important underlying pathogenetic 
mechanism of NP-C.
Pharmacokinetics
The pharmacokinetics of miglustat have not been assessed in 
patients with NP-C, but are likely to be similar to those seen in 
patients with GD1. In patients with GD1, miglustat is rapidly 
absorbed after oral administration; the time taken to reach 
maximal plasma drug concentration (tmax) is approximately 
2 to 2.5 hours. The absolute bioavailability of miglustat is at 
least 80%. Although taking miglustat with a fatty meal can 
extend tmax, this effect is not considered clinically relevant. 
The pharmacokinetics of miglustat in GD1 are approximately 
dose-proportional,46, 47 and the mean volume of distribution 
is large, at around 83 to 105 L. This indicates that miglustat 
is not restricted to the bloodstream, and can distribute into 
extravascular tissues.47 Data from animal studies have con-
firmed that miglustat has specific physico-chemical proper-
ties (including lipid solubility and electrical charge) that 
allow wide tissue distribution, and the ability to cross the 
blood–brain barrier.48 This wide tissue distribution is essential 
to enable miglustat to reach all of the affected body tissues 
and organs in NP-C, particularly the brain.
Although miglustat can penetrate the blood–brain barrier, 
concentrations of the drug in the cerebrospinal fluid are lower 
than plasma levels. To compensate for this, a higher dose 
than the 100 mg 3 times daily recommended in GD1, which 
is primarily a systemic disease, is required for patients with 
NP-C. A dose of 200 mg three times daily was therefore 
selected for adult patients, which should be reduced in 
proportion to body surface area in pediatric patients. The 
three-times-daily dosing regimen is a result of the fact that 
miglustat remains in the body for around 8 hours, and must 
therefore be taken three times daily to maintain therapeutic Therapeutics and Clinical Risk Management 2009:5 881
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levels. Miglustat is not metabolized in vivo, and so has a 
low mean rate of clearance from the body (mainly via the 
kidneys) of 11.8 to 13.8 L/hour.47 The half-life of miglustat 
of 6 to 7 hours predicts that steady-state conditions will be 
achieved soon after treatment initiation. In clinical studies 
of miglustat in patients with GD1, steady-state was reached 
after 4 to 6 weeks of treatment.49
effects of miglustat in animal models 
of NP-C
The discovery that miglustat has the ability to cross the 
blood–brain barrier and reduce intracellular lipid storage in 
NP-C cell culture models led to a study of the effect of the 
drug in animal models of NP-C. In NP-C mice, only 11% of 
animals treated with miglustat developed an NP-C clinical 
phenotype after 50 to 62 days, while 78% of non-treated mice 
displayed the same manifestations.50 By 65 to 78 days, all 
of the non-treated mice had developed symptoms of NP-C, 
compared with 56% of treated mice. Mean survival in treated 
mice was 89 days, compared with 67 days in untreated mice.50 
Cerebellar pathology and storage of GM2 and GM3 gangliosides 
were also shown to be reduced in the treated mice compared 
with those that did not receive treatment. These findings 
suggest that miglustat can delay the progression of NP-C 
and prolong survival. Similarly, in a feline model of NP-C, 
cats treated with miglustat showed a delay in the onset and 
progression of symptoms.50 Ganglioside accumulation in the 
brain was also reduced.50
Efficacy
Following positive results from preclinical and animal studies, 
a prospective, randomized clinical trial (OGT-918-007) was 
designed and implemented to assess the efficacy, safety and 
tolerability of miglustat in patients with NP-C. Juvenile or 
adult patients (aged 12 years or older) were enrolled, and 
randomized to either miglustat 200 mg three times daily 
(n = 20) or standard care (n = 9).43 The randomized phase of the 
study was 12 months in duration. In parallel to this randomized 
trial, a pediatric sub-study assessed the effects of miglustat 
in children (n = 12) aged from 4 to 11 years with NP-C.43,51 
These pediatric patients received open-label miglustat for 
12 months at a dose adjusted for their body weight.
In adult and juvenile patients, improvements in the 
primary endpoint, horizontal saccadic eye movement peak 
velocity (HSEM-α) were seen in miglustat-treated patients 
versus those receiving standard care at Month 12, a finding 
that was statistically significant when patients receiving 
concomitant benzodiazepine therapy were excluded from 
the analysis.43 Benzodiazepines are known to impair saccadic 
eye movements. Benefits of miglustat therapy were also seen 
on measures of swallowing capacity, auditory acuity and 
ambulation. An overall mean improvement in HSEM-α was 
also seen in pediatric patients at Month 12.43
Adult and juvenile patients who completed the random-
ized phase of the study were eligible to continue treatment in 
a 12-month, non-controlled extension phase. Following this, 
patients could enter a long-term ‘continued extension’ phase. 
Similarly, pediatric patients who completed the first 12 months 
were eligible to continue treatment for a 12-month exten-
sion period followed by a long-term ‘continued extension’ 
phase. Long-term data from the open-label extension phases 
have also been reported.52 In all patients who had at least 
one assessment during the continued extension phase (past 
24 months, n = 14), swallowing capacity was improved in 
more than 75% patients. Median standard ambulation index 
scores indicated stabilization.52 A disease stability analysis 
of 19 adult or juvenile patients who completed at least 
12 months of miglustat therapy, based on four key parameters 
of disease progression (HSEM-α, swallowing, ambulation and 
cognition), showed that 68% had stable disease after treatment 
(unpublished data Wraith et al 2009).
In pediatric patients, the overall mean improvement in 
HSEM-α velocity was maintained at Month 24, and stabiliza-
tion of ambulation and swallowing was also achieved.51 The 
analysis of key parameters of disease progression revealed 
that 80% of pediatric patients who entered the extension 
phase had stable disease by Month 24, suggesting that 
miglustat provided similar benefits in pediatric patients as in 
juveniles and adults.51 These findings indicate that long-term 
miglustat therapy stabilizes neurological manifestations in 
pediatric, juvenile and adult patients with NP-C.
In addition to the prospective clinical trial, the effect 
of miglustat on the progression of neurological disease 
in patients with NP-C has been studied in an interna-
tional, multicentre, observational cohort study. Sixty-six 
patients with NP-C treated with miglustat in clinical prac-
tice at 25 expert centers were assessed retrospectively53 
using a modified disease-specific disability scale.32 The 
scale analyzed four key parameters of neurological disease 
progression in NP-C: ambulation, manipulation, language and 
swallowing. The mean annual progression was +0.11 score 
units/year on the disability scale from diagnosis to treatment 
start, indicating considerable disease progression prior to 
initiation of miglustat therapy. Annual progression decreased 
to −0.01 score units/year from treatment start to the last clinic 
visit, indicating disease stabilization with miglustat therapy. Therapeutics and Clinical Risk Management 2009:5 882
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Previous epidemiological studies have established that NP-
C tends to present in a range of different clinical forms 
defined by patients’ age at onset of neurological symptoms: 
early-infantile (onset 3 months to 2 years), late-infantile 
(onset 2 to 6 years), juvenile (onset 6–15 years) and adult 
(onset 15 years).20,32,33,54 When the patients in the retrospec-
tive miglustat cohort were divided into three age groups, sta-
bilization of neurological disease was observed in all groups. 
However, the magnitude of the effect was greater in patients 
diagnosed in late childhood (6–11 years) and in juveniles and 
adults (12 years and older), compared with those diagnosed 
in early childhood (younger than 6 years) (Figure 2).
The efficacy of miglustat in patients with NP-C has 
also been demonstrated in a number of case series.41,55,56 
In two Taiwanese patients treated with miglustat for one year, 
cognitive improvement was observed in one patient and liver 
and spleen volumes and chitotriosidase levels were stabilized 
in both patients.55 One patient had severe swallowing diffi-
culties at baseline; this was greatly improved with miglustat 
treatment. The patient that showed improved cognition had 
a later disease onset (late childhood) compared with the 
second patient, whose presenting symptoms occurred in 
infancy. A report of a Brazilian patient with early childhood 
onset NP-C who received miglustat for 12 months indicated 
improvements in speech, ataxia, seizures, hypotonia, gaze 
palsy and behavioral symptoms, and particularly ambulation.56 
Brain magnetic resonance spectroscopy was used to assess 
the effects of 24 months’ miglustat treatment in three patients 
with NP-C. A decrease in choline/creatine ratio was identified 
as a potential marker for treatment efficacy, as a sustained 
decrease correlated with mild improvement or stabilization of 
clinical manifestations (swallowing, dysarthria, awareness or 
ambulation) achieved with miglustat therapy.41 The choline/
creatine ratio is a measure of membrane destruction, or gliosis, 
so can be used as a marker for brain dysfunction.41 Together, 
these findings support data from the prospective clinical trial 
and observational cohort study, indicating beneficial therapeu-
tic effects of miglustat in patients with NP-C.
Recommended clinical  
use of miglustat
An expert panel convened in Paris, France in January 2009 to 
discuss best care practices for NP-C. Recommendations on the 
management of NP-C patients based on consensus between the 
experts at the meeting were provided, including guidance on 
how to initiate miglustat therapy.3 The experts recommended 
that miglustat treatment should be started immediately in diag-
nosed patients with any type of neurological manifestations. 
Meanwhile, in patients who do not have neurological mani-
festations but for whom there is a known family history and 
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disease course, treatment should be commenced at or before 
the anticipated time of neurological symptom onset. However, 
patients with early-infantile onset NP-C, and those with severe 
dementia in the terminal stage of the disease, are less likely to 
benefit from treatment with miglustat and decisions to start 
treatment should be made on a case by case basis. Based on 
these guidelines, a protocol for the initiation of miglustat 
treatment in NP-C was developed (Figure 3).
The recommended dose of 200 mg three times daily for 
adult patients with NP-C should be adjusted according to 
body surface area for younger patients, as shown in Table 1.3 
In general miglustat therapy should be continued as long as 
patients continue to derive discernable therapeutic benefits with 
an acceptable tolerability and safety profile. In early-infantile 
onset disease it can take up to 6 to 12 months to see discernable 
clinical benefits and 2 to 3 years in later-onset disease. Given 
the high variability of NP-C in terms of symptomatology and 
rate of progression, decisions to alter or discontinue treat-
ment with miglustat should be based on individual patient 
characteristics, in consultation with the patient and their 
family members. In cases where there is a perceived lack of 
response, dose manipulation can be undertaken with careful 
consideration of risk versus benefit and patient tolerability.3
A disease-specific registry to evaluate the long-term disease 
course in patients with NP-C, both untreated and treated with 
miglustat, has been designed by an international scientific 
committee57 and will be implemented in late 2009. One of the 
objectives of this registry is to describe the natural history of 
NP-C and to evaluate the treatment experience of patients with 
NP-C, including the longitudinal assessment of outcomes. The 
registry will employ the functional disability scale32 to assess 
the progression of neurological disease. This first interna-
tional registry for patients with NP-C will provide important 
further information on patient outcomes during miglustat 
therapy in real-world, clinical practice settings, and will bring 
together information from a larger number of patients.
Safety and tolerability
Findings from the prospective clinical trial demonstrated 
that miglustat has a similar safety and tolerability profile in 
pediatric and adult and juvenile patients with NP-C to that 
seen in patients with GD1.49,58,59 The most frequently reported 
treatment-emergent adverse events with miglustat therapy 
were mild or moderate diarrhea, flatulence and weight loss 
(Table 2).43,51 The incidence of gastrointestinal adverse events 
and mild to moderate weight loss tended to decrease over time 
on continued therapy. No deterioration of growth rates was 
noted in pediatric or juvenile patients treated with miglustat.51 
Neurological adverse events such as tremor, headache and 
fatigue were also commonly reported, but were generally 
NPC-diagnosis confirmeda
Family history
Estimated time of 
neurological symptom
onset knownb
Treat at or before
anticipated time of onset
Monitor
Treat
Yes
Yes
No
No
No Yes
Monitor
Any kind of neurological
manifestations
Figure 3 Protocol for initiation of miglustat treatment in NP-C. Reproduced with permission from Wraith Je, Baumgartner MR, Bembi B, et al. Recommendations on the 
diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab. 2009;98:152–165.3 Copyright © 2009 elsevier.
Notes: aBiochemical and/or molecular-genetic diagnosis, with or without systemic or other clinical signs and symptoms; bPatients asymptomatic or with isolated splenomegaly, 
and with one or more older siblings in whom the time of neurological symptom onset and rate of progression are known.Therapeutics and Clinical Risk Management 2009:5 884
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mild or moderate in intensity. Although six juvenile or adult 
patients and five pediatric patients experienced serious 
adverse events during the full 24-month study period, none 
of these events were considered related to miglustat therapy. 
Withdrawals due to adverse events occurred in four adult or 
juvenile patients and two pediatric patients. Mild reductions 
in platelet counts that were not associated with bleeding were 
observed in some patients. Continued monitoring of platelet 
counts is recommended in patients who show a reduction that 
is not associated with bleeding.47
When miglustat was first launched in Europe for the 
treatment of GD1, a post-authorization surveillance program 
was established. Patients with NP-C treated with miglustat in 
clinical practice are also included in the database.60 In March 
2009, data had been collected from 102 patients with NP-C 
across 11 European countries. Miglustat was well-tolerated, 
with a safety and tolerability profile matching that seen in 
the clinical trials. Over 60% of patients had received more 
than 24 months’ miglustat therapy, and 38% had received 
36 months’ treatment, demonstrating the long-term safety of 
miglustat in patients with NP-C.60
There is some evidence to suggest that miglustat may 
have an effect on fertility. In animal studies, administration 
of miglustat to male mice resulted in reversible infertility in 
some inbred mouse strains.61 In the same study normal male 
fertility was reported in the rabbit. A pilot study of the effects 
of miglustat on spermatogenesis in healthy human men did not 
detect any effect on sperm motility, morphology or concentra-
tion during 6 weeks of miglustat therapy.61,62 However, further 
data are required to confirm these findings; in the meantime 
it is recommended that male patients should cease miglustat 
therapy before seeking to conceive, and maintain reliable 
contraceptive methods. Miglustat may also have an effect 
on fertility in women; for this reason miglustat should not be 
used during pregnancy or by breast-feeding women.47
Patient and carer perspective
The prospective clinical trial of miglustat in NP-C did 
not include any quality of life or patient satisfaction and 
acceptability measures, so case reports are the main source 
of data on the patient and caregiver perspective. Miglustat 
has been shown to have a positive impact upon social 
behavior, depression and affective and attention problems 
in a Brazilian patient with NP-C,56 potentially leading to 
improved quality of life, not only for the patient but also for 
the patient’s family and carers. This was reflected in the case 
study of two Taiwanese patients, in which families of both 
patients expressed satisfaction with miglustat treatment.55 
One of the patients also indicated satisfaction with treatment; 
the second patient was not able to express his comments 
despite improvements in communication during therapy.55 
In our own clinic, we have a number of patients who have 
achieved disease stabilization on miglustat to the satisfaction 
of both the patients and their parents.
Conclusions
The efficacy, safety and tolerability of miglustat in 
juvenile, adult and pediatric patients with NP-C have been 
demonstrated in a prospective clinical trial and a retrospective 
observational study,43,51–53 supported by findings from 
preclinical studies,44,48,50 case reports41,55,56 and the miglustat 
post-authorization surveillance program.60 Miglustat may 
stabilize the progression of neurological manifestations in 
NP-C, a significant achievement in this disease, for which 
there has previously been no disease-modifying therapy 
available. Experts agree that stabilization of neurological 
disease is the best attainable therapeutic goal in patients 
diagnosed with NP-C, due to the fact that irreversible damage 
or loss of neurons will likely already have occurred by the 
time the diagnosis of NP-C is made.3 To date, miglustat is the 
only approved, disease-specific therapy for the treatment of 
NP-C. With the extension of miglustat’s indication to include 
the treatment of progressive neurological disease in adult and 
pediatric patients with NP-C, treatment can now be aimed at 
stabilizing neurological disease progression. This represents 
a significant step forward in the management and treatment 
of this severely debilitating disorder.
Acknowledgments and disclosures
Alpha-Plus Medical Communications Ltd. provided 
medical writing assistance on this manuscript, paid for 
by Actelion Pharmaceuticals Ltd. JW has received travel 
grants and research grant funds, has carried out paid and 
unpaid consultancy work for Actelion Pharmaceuticals Ltd, 
Genzyme Corporation, Shire Human Genetics Therapies 
and Zacharon Pharmaceuticals, and is supported by the 
Manchester Academic Health Sciences Centre (MAHSC) 
Table 1 Recommended miglustat dose alteration according to 
body surface area3
Body surface area (m2) Recommended dose
1.25 200 mg three times a day
0.88–1.25 200 mg twice a day
0.73–0.88 100 mg three times a day
0.47–0.73 100 mg twice a day
0.47 100 mg once a dayTherapeutics and Clinical Risk Management 2009:5
Miglustat in Niemann-Pick disease type C Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
885
and the NIHR Manchester Biomedical Research Centre. 
JI has received travel expenses and honoraria from Actelion 
Pharmaceuticals Ltd.
References
  1.  Vanier MT, Millat G. Niemann-Pick disease type C. Clin Genet. 
2003;64:269–281.
  2.  Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal 
storage disorders. JAMA. 1999;281:249–254.
  3.  Wraith JE, Baumgartner MR, Bembi B, et al. Recommendations on the 
diagnosis and management of Niemann-Pick disease type C. Mol Genet 
Metab. 2009;98:152–165.
  4.  Carstea ED, Morris JA, Coleman KG, et al. Niemann-Pick C1 disease 
gene: homology to mediators of cholesterol homeostasis. Science. 
1997;277:228–231.
  5.  Millat G, Bailo N, Molinero S, Rodriguez C, Chikh K, Vanier MT. 
Niemann-Pick C disease: use of denaturing high performance liquid 
chromatography for the detection of NPC1 and NPC2 genetic variations 
and impact on management of patients and families. Mol Genet Metab. 
2005;86:220–232.
Table 2 Treatment-emergent adverse eventsa in pediatric51 and adult/juvenile patients (unpublished data Wraith et al 2009) with long-term 
miglustat therapy (up to 52 and 66 months, respectively)
Adverse event Pediatric (N = 12) Adult/juvenile (N = 28)
n % n %
Diarrhea 8 66.7 25 89.3
Tremor 7 58.3 16 57.1
Headache 6 50.0 11 39.3
Cough 5 41.7 7 25.0
Fatigue 5 41.7 13 46.4
Gait disturbance 5 41.7 – –
vomiting 5 41.7 9 32.1
Ataxia 4 33.3 – –
Dysphagia 4 33.3 7 25.0
Dystonia 4 33.3 7 25.0
Flatulence 4 33.3 18 64.3
Gaze palsy 4 33.3 – –
Nasopharyngitis 4 33.3 12 42.9
Splenomegaly 4 33.3 – –
Cataplexy 3 25.0 – –
Constipation 3 25.0 – –
Deafness 3 25.0 – –
Dementia 3 25.0 – –
Dysarthria 3 25.0 – –
epistaxis 3 25.0 – –
Fall 3 25.0 7 25.0
Hyperreflexia 3 25.0 – –
Lethargy 3 25.0 – –
Pyramidal tract syndrome 3 25.0 – –
Respiratory tract infection 3 25.0 – –
Sinusitis 3 25.0 – –
Weight decrease 3 25.0 21 75.0
Upper abdominal pain – – 11 39.3
Insomnia – – 9 32.1
Nausea – – 9 32.1
Confusional state – – 8 28.6
Abnormal NCvb – – 8 28.6
Abdominal pain – – 7 25.0
Paresthesia – – 7 25.0
Sleep disorder – – 7 25.0
Notes: aOccurring in 25% of patients, overall; bNCv = nerve conduction velocity.Therapeutics and Clinical Risk Management 2009:5 886
Wraith and Imrie Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  6.  Naureckiene S, Sleat DE, Lackland H, et al. Identification of HE1 
as the second gene of Niemann-Pick C disease. Science. 2000;290: 
2298–2301.
  7.  Millat G, Chikh K, Naureckiene S, et al. Niemann-Pick disease type C: 
spectrum of HE1 mutations and genotype/phenotype correlations in the 
NPC2 group. Am J Hum Genet. 2001;69:1013–1021.
  8.  Subramanian K, Balch WE. NPC1/NPC2 function as a tag team duo to 
mobilize cholesterol. Proc Natl Acad Sci U S A. 2008;105:15223–15224.
  9.  te Vruchte D, Lloyd-Evans E, Veldman RJ, et al. Accumulation of 
glycosphingolipids in Niemann-Pick C disease disrupts endosomal 
transport. J Biol Chem. 2004;279:26167–26175.
10.  Mukherjee S, Maxfield FR. Lipid and cholesterol trafficking in NPC. 
Biochim Biophys Acta. 2004;1685:28–37.
11.  Sleat DE, Wiseman JA, El-Banna M, et al. Genetic evidence for non-
redundant functional cooperativity between NPC1 and NPC2 in lipid 
transport. Proc Natl Acad Sci U S A. 2004;101:5886–5891.
12.  Sokol J, Blanchette-Mackie J, Kruth HS, et al. Type C Niemann-
Pick disease. Lysosomal accumulation and defective intracellular 
mobilization of low density lipoprotein cholesterol. J Biol Chem. 
1988;263:3411–3417.
13.  Kwon HJ, Abi-Mosleh L, Wang ML, et al. Structure of N-terminal 
domain of NPC1 reveals distinct subdomains for binding and transfer 
of cholesterol. Cell. 2009;137:1213–1224.
14.  Storch J, Xu Z. Niemann-Pick C2 (NPC2) and intracellular cholesterol 
trafficking. Biochim Biophys Acta. 2009;1791:671–678.
15.  Patterson MC, Vanier MT, Suzuki K, et al. Niemann-Pick disease type C: 
a lipid trafficking disorder. In: Scriver CR, Beaudet AL, Sly WS, Valle D, 
Childs B, Vogelstein B, eds. The Metabolic and Molecular Bases of 
Inherited Disease. New York: McGraw-Hill; 2001:3611–3633.
16.  Pentchev PG, Gal AE, Booth AD, et al. A lysosomal storage disorder 
in mice characterized by a dual deficiency of sphingomyelinase and 
glucocerebrosidase. Biochim Biophys Acta. 1980;619:669–679.
17.  Rodriguez-Lafrasse C, Rousson R, Pentchev PG, Louisot P, Vanier MT. 
Free sphingoid bases in tissues from patients with type C Niemann-Pick 
disease and other lysosomal storage disorders. Biochim Biophys Acta. 
1994;1226:138–144.
18.  Vanier MT. Biochemical studies in Niemann-Pick disease. I. Major sphin-
golipids of liver and spleen. Biochim Biophys Acta. 1983;750:178–184.
19.  Vanier MT. Lipid changes in Niemann-Pick disease type C brain: 
personal experience and review of the literature. Neurochem Res. 
1999;24:481–489.
20.  Wraith JE, Baumgartner MR, Bembi B, et al. Recommendations on 
the diagnosis and management of Niemann-Pick disease type C. Mol 
Genet Metab. 2009;98:152–165.
21.  Philippart M, Engel J Jr, Zimmerman EG. Gelastic cataplexy in 
Niemann-Pick disease group C and related variants without generalized 
sphingomyelinase deficiency. Ann Neurol. 1983;14:492–483.
22.  Kandt RS, Emerson RG, Singer HS, Valle DL, Moser HW. Cataplexy 
in variant forms of Niemann-Pick disease. Ann Neurol. 1982;12: 
284–288.
23.  Mellon SH, Gong W, Schonemann MD. Endogenous and synthetic 
neurosteroids in treatment of Niemann-Pick Type C disease. Brain Res 
Rev. 2008;57:410–420.
24.  Liu B, Turley SD, Burns DK, Miller AM, Repa JJ, Dietschy JM. Rever-
sal of defective lysosomal transport in NPC disease ameliorates liver 
dysfunction and neurodegeneration in the npc1-/- mouse. Proc Natl 
Acad Sci U S A. 2009. 2009;106:2377–2382.
25.  Hsu YS, Hwu WL, Huang SF, et al. Niemann-Pick disease type C 
(a cellular cholesterol lipidosis) treated by bone marrow transplantation. 
Bone Marrow Transplant. 1999;24:103–107.
26.  Choudhury A, Dominguez M, Puri V, et al. Rab proteins mediate 
Golgi transport of caveola-internalized glycosphingolipids and cor-
rect lipid trafficking in Niemann-Pick C cells. J Clin Invest. 2002;109: 
1541–1850.
27.  Walter M, Davies JP, Ioannou YA. Telomerase immortalization 
upregulates Rab9 expression and restores LDL cholesterol egress from 
Niemann-Pick C1 late endosomes. J Lipid Res. 2003;44:243–253.
28.  Kaptzan T, West SA, Holicky EL, et al. Development of a Rab9 
transgenic mouse and its ability to increase the lifespan of a murine model 
of Niemann-Pick type C disease. Am J Pathol. 2009;174:14–20.
29.  Lloyd-Evans E, Morgan AJ, He X, et al. Niemann-Pick disease type C1 
is a sphingosine storage disease that causes deregulation of lysosomal 
calcium. Nat Med. 2008;14:1247–1255.
30.  Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin 
is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 
1994;269:8362–8365.
31.  Wraith JE, Guffon N, Rohrbach M, et al. Natural history of Niemann-
Pick disease type C in a multicentre observational retrospective cohort 
study. Mol Genet Metab. 2009;98:250–254.
32.  Iturriaga C, Pineda M, Fernandez-Valero EM, Vanier MT, Coll MJ. 
Niemann-Pick C disease in Spain: clinical spectrum and development 
of a disability scale. J Neurol Sci. 2006;249:1–6.
33.  Imrie J, Dasgupta S, Besley GT, et al. The natural history of Niemann-
Pick disease type C in the UK. J Inherit Metab Dis. 2007;30:51–59.
34.  Oyama K, Takahashi T, Shoji Y, et al. Niemann-Pick disease type C: 
cataplexy and hypocretin in cerebrospinal fluid. Tohoku J Exp Med. 
2006;209:263–267.
35.  Paciorkowski AR, Westwell M, Ounpuu S, et al. Motion analysis of a 
child with Niemann-Pick disease type C treated with miglustat. Mov 
Disord. 2008;23:124–128.
36.  Schiffmann R. Niemann-Pick disease type C. From bench to bedside. 
JAMA. 1996;276:561–564.
37.  Yanjanin NM, Velez JI, Gropman A, et al. Linear clinical progression, 
independent of age of onset, in Niemann-Pick disease, type C. Am J 
Med Genet B Neuropsychiatr Genet. 2009. [Epub ahead of print] May 4. 
DOI:10.1002/ajmg.b.30969.
38.  Garver WS, Francis GA, Jelinek D, et al. The National Niemann-Pick 
C1 disease database: report of clinical features and health problems. 
Am J Med Genet A. 2007;143:1204–1211.
39.  Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical 
method for grading the cognitive state of patients for the clinician. 
J Psychiatr Res. 1975;12:189–198.
40.  Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assess-
ment Battery at bedside. Neurology 2000;55:1621–1626.
41.  Galanaud D, Tourbah A, Lehéricy S, et al. 24 month-treatment with 
miglustat of three patients with Niemann-Pick disease type C: Follow 
up using brain spectroscopy. Mol Genet Metab. 2008;96:55–58.
42.  Abel LA, Walterfang M, Fietz M, Bowman EA, Velakoulis D. Saccades 
in adult Niemann-Pick disease type C reflect frontal, brainstem, and 
biochemical deficits. Neurology. 2009;72:1083–1086.
43.  Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for 
treatment of Niemann-Pick C disease: a randomised controlled study. 
Lancet Neurol. 2007;6:765–772.
44.  Lachmann RH, te Vruchte D, Lloyd-Evans E, et al. Treatment with 
miglustat reverses the lipid-trafficking defect in Niemann-Pick disease 
type C. Neurobiol Dis. 2004;16:654–658.
45.  Lloyd-Evans E, Pelled D, Riebeling C, et al. Glucosylceramide and glu-
cosylsphingosine modulate calcium mobilization from brain microsomes 
via different mechanisms. J Biol Chem. 2003;278:23594–23599.
46.  Heitner R, Elstein D, Aerts J, Weely S, Zimran A. Low-dose 
N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood 
Cells Mol Dis. 2002;28:127–133.
47.  Miglustat (Zavesca®) summary of product characteristics. EMEA, 2009. 
URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/zavesca/
H-435-PI-en.pdf. Accessed 15 May, 2009.
48.  Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue 
distribution of the glucosylceramide synthase inhibitor miglustat in 
the rat. Xenobiotica. 2007;37:298–314.
49.  Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher’s 
disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate 
biosynthesis. Lancet. 2000;355:1481–1485.
50.  Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for 
glycosphingolipids in Niemann-Pick disease type C. Curr Biol. 
2001;11:1283–1287.Therapeutics and Clinical Risk Management 2009:5
Therapeutics and Clinical Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
Therapeutics and Clinical Risk Management is an international, peer-
reviewed journal of clinical therapeutics and risk management, focusing 
on concise rapid reporting of clinical studies in all therapeutic areas, 
outcomes, safety, and programs for the effective, safe, and sustained 
use of medicines. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
887
Miglustat in Niemann-Pick disease type C Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
51.  Patterson P, Vecchio D, Jacklin E, et al. Long-term miglustat therapy in 
children with Niemann-Pick disease type C. J Child Neurol. In press.   
2009.
52.  Patterson MC, Vecchio D, Jacklin E, Wraith JE. Miglustat in Niemann-
Pick disease Type C (NPC): long-term data from a clinical trial. 
58th Annual Meeting of the American Society of Human Genetics. 
Philadelphia, USA; 2008.
53.  Pineda M, Wraith JE, Mengel E, et al. Miglustat in patients with 
Niemann-Pick Type C disease (NP-C): a multicentre observational 
retrospective cohort study. Mol Genet Metab. 2009;98:243–249.
54.  Vanier MT, Wenger DA, Comly ME, Rousson R, Brady RO, Pentchev PG. 
Niemann-Pick disease group C: clinical variability and diagnosis based 
on defective cholesterol esterification. A collaborative study on 70 
patients. Clin Genet. 1988;33:331–348.
55.  Chien YH, Lee NC, Tsai LK, et al. Treatment of Niemann-Pick disease 
type C in two children with miglustat: initial responses and maintenance 
of effects over 1 year. J Inherit Metab Dis. 2007;30:826.
56.  Santos ML, Raskin S, Telles DS, et al. Treatment of a child diagnosed 
with Niemann-Pick disease type C with miglustat: A case report 
in Brazil. J Inherit Metab Dis. 2008. [Epub ahead of print] Oct 21. 
DOI:10.1007/s10545-008-0923-9.
57.  Pineda M, Wraith JE, Wijburg FA, et al. Designing a disease registry 
for Niemann-Pick disease type C. 19th Meeting of the European 
Neurological Society (ENS). Milan, Italy; 2009.
58.  Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative 
study of miglustat in type I Gaucher disease: efficacy and 
tolerability over 24 months of treatment. Clin Ther. 2005;27: 
1215–1227.
59.  Elstein D, Dweck A, Attias D, et al. Oral maintenance clinical trial 
with miglustat for type I Gaucher disease: switch from or combi-
nation with intravenous enzyme replacement. Blood. 2007;110: 
2296–2301.
60.  Pineda M, Wraith JE, Mengel E, Imrie J, Schwierin B, Bembi B. Safety 
monitoring of miglustat in patients with Niemann-Pick disease type C. 
19th Meeting of the European Neurological Society (ENS). Milan, Italy; 
2009.
61.  Bone W, Walden CM, Fritsch M, et al. The sensitivity of murine 
spermiogenesis to miglustat is a quantitative trait: a pharmacogenetic 
study. Reprod Biol Endocrinol. 2007;5:1.
62.  Amory JK, Muller CH, Page ST, et al. Miglustat has no apparent 
effect on spermatogenesis in normal men. Hum Reprod. 2007;22: 
702–707.